DRUGGABLE GENOME AND PROTEOME Karen A. Méndez L “the most fruitful basis for the discovery of a new drug is to start with an old drug” (James W Black,

Slides:



Advertisements
Similar presentations
Postgraduate Course in Pharmaceutical Medicine A warm welcome to all participants.
Advertisements

Professor Robin Leatherbarrow Head of Biological Chemistry Department of Chemistry.
Life Sciences Life Sciences Richard M. Eglen ELRIG, Manchester, UK September 7-8, 2011 High throughput screening and assay development – fit for purpose?
Chemical Biology 1 – Pharmacology Methods for studying protein function – Loss of Function 1. Gene knockouts 2. Conditional knockouts 3. RNAi.
Data Integration for Cancer Genomics. Personalized Medicine Tumor Board Question: given all we know about a patient, what is the “optimal” treatment?
Новая парадигма разработки лекарств: как мы и хотели это делать в 1999 году Виталий Пруцкий, Глава по информационному обеспечению R&D, «АстраЗенека Россия»
From Chemoinformatics to Systems Chemical Biology Irene Kouskoumvekaki, Associate Professor, Computational Chemical Biology, CBS, DTU-Systems Biology #27803,
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Protein Therapeutics: a summary and pharmacological classification
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Pan-assay interference compounds
Identify and Investigate the role of enzymes.
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Takeda Pharmaceutical Inc.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Phylogeny in Drug Discovery?
Integrating Microflow NMR into Fragment-based Drug Discovery Daniel S. Sem Chemical Proteomics Facility at Marquette (CPFM) Department of Chemistry Marquette.
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
R genes: Structure, recognition, signaling, & evolution – part 1 Major classes of R genes R gene structure Early signaling events R gene evolution.
EXPLORING CHEMICAL SPACE FOR DRUG DISCOVERY Daniel Svozil Laboratory of Informatics and Chemistry.
FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.
From Signal Transduction to Targeted Therapy (Fall 2010) Pin Ling ( 凌 斌 ), Ph.D. Department of Microbiology & Immunology, NCKU ext 5632
Finish up array applications Move on to proteomics Protein microarrays.
Next Generation Sequencing and its data analysis challenges Background Alignment and Assembly Applications Genome Epigenome Transcriptome.
Text Mining Special Interest Group Stuart Murray, Wyeth Research Novartis Institute for Biomedical Research, Cambridge, MA 6-8 th October 2004.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
Agent-based methods for translational cancer multilevel modelling Sylvia Nagl PhD Cancer Systems Science & Biomedical Informatics UCL Cancer Institute.
PHARMACOLOGY Searches for new drugs Investigates effects of known drugs WHAT IS PHARMACOLOGY ? pharmacologists are drug hunters mechanism of action, evidence.
Genomes To Life Biology for 21 st Century A Joint Initiative of the Office of Advanced Scientific Computing Research and Office of Biological and Environmental.
High throughput Protein Measurement Techniques Harin Kanani.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
DuPont Pharmaceuticals Company Utilization of Spotfire™ in Quality Assessment & Analysis of Screening Data Thomas D.Y. Chung, Ph.D. Sr. Director, Leads.
Drug–Target Network Hussein Hijazi Fall 2012 Michigan State University 1.
ENZYME NOTES. Chemical Reactions Chemical Reaction – process that changes one set of chemicals into another set of chemicals Reactants – elements or compounds.
The type of target influence the type of drug Main drugs’ categories –Small molecules –Biologicals (e.g. antibodies, hormones, etc) The drug discovery.
Organic Pedagogical Electronic Network C–H bond Hydroxylation at Non-Heme Carboxylate-Bridged Diiron Centers Omar Villanueva, Cora MacBeth Emory University.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Module 5: Future 1 Canadian Bioinformatics Workshops
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Chapter 2. Amino acids Protein structure Primary:
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Molecular Modeling in Drug Discovery: an Overview
Structural Bioinformatics in Drug Discovery Melissa Passino.
Screening of allosteric inhibitors and inhibitors of protein-protein interactions Joel Eggert.
Intersecting different databases to define the inner and outer limits of the data-supported druggable proteome
Application of High-Throughput Methodology to Human Drug Targets
Biotechnology Objectives: At the end of this lecture we will be able to identify and describe the uses of biotechnology in society.
Structural Bioinformatics in Drug Discovery
Sponsored by: APS and ASPET Co-sponsors: Burroughs Wellcome Fund
Figure 5 Two approaches to therapeutic genome editing
Lixia Yao, James A. Evans, Andrey Rzhetsky  Trends in Biotechnology 
Figure 2 The network of chronic diseases and their mutual influences
Nat. Rev. Cardiol. doi: /nrcardio
Bioinformatic and Computational research in Biological Sciences
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Standards Development for Metabolomics
The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.
The increasing availability of quantitative biological data from the human genome project, coupled with advances in instrumentation, reagents, methodologies,
Figure 5 Systems biological model of IBS
Joel T. Dudley, Atul J. Butte  Gastroenterology 
Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,
Nat. Rev. Nephrol. doi: /nrneph
Figure 1 A large number of genes are potentially associated with CIPN
Figure 4 Intracellular distribution and
Nat. Rev. Neurol. doi: /nrneurol
Three drug delivery strategies for crossing the blood-brain barrier.
Targeted Therapeutic Drug Monitoring for Direct Oral Anticoagulants: What Is Its Potential Place and Can It Limit Black Swan Events?  D. George Wyse,
An isogenic cell line screen reveals genomic drivers of drug response.
Presentation transcript:

DRUGGABLE GENOME AND PROTEOME Karen A. Méndez L “the most fruitful basis for the discovery of a new drug is to start with an old drug” (James W Black, Nobel de Medicina 1988)

Druggability Thomas H Keller, et al. Current Opinion in Chemical Biology 2006, 10:357–361

Drug- like compounds Thomas H Keller, et al. Current Opinion in Chemical Biology 2006, 10:357–361 Lipinski (2001) -- ˃ Rule of 5 (RO5)

Rule of 5  1. RO5 applies only to compounds that are delivered by the oral route.  2. RO5 applies only to compounds that are absorbed by passive mechanisms  3. There are important exceptions (MW and natural compounds).  4. RO5 compliant compounds are not automatically good drugs

Disease and Druggable Genome Dixon SJ and Stockwell BR (2009) Hopkins y Groom (2002)

Overington et al. Nature Reviews Drug Discovery 5, 993–996 (December 2006) | doi: /nrd2199

Druggable Proteome Door: Protein Lock: Drug Binding Site Key: Drug Pharmaceutically Tractable Genome Yıldırım et al, Drug–target network. NATURE BIOTECHNOLOGY VOLUME 25 NUMBER 10 OCTOBER 2007

Druggable Network Yıldırım et al, Drug–target network. NATURE BIOTECHNOLOGY VOLUME 25 NUMBER 10 OCTOBER 2007

Distribution of Drugs and Drug Targets Yıldırım et al, Drug–target network. NATURE BIOTECHNOLOGY VOLUME 25 NUMBER 10 OCTOBER 2007

Distribution of Drugs and Drug Targets Yıldırım et al, Drug–target network. NATURE BIOTECHNOLOGY VOLUME 25 NUMBER 10 OCTOBER 2007

References  Dixon SJ and Stockwell BR (2009) Identifying druggable disease-modifying gene products, Curr Opin Chem Biol 13: 549–555  Yıldırım et al, Drug–target network. NATURE BIOTECHNOLOGY VOLUME 25 NUMBER 10 OCTOBER 2007  Overington et al. Nature Reviews Drug Discovery 5, 993–996 (December 2006) | doi: /nrd2199  Thomas H Keller, et al. Current Opinion in Chemical Biology 2006, 10:357– 361  Zheng CJ et al. (2006) Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics,  Pharmacol Rev 58: 259–279  Russ AP and Lampel S (2005) The druggable genome:an update, Drug Discov Today 10 (23/24):  Hopkins AL and Groom CR (2002) The druggable genome, Nat Rev Drug Discov 1: